Transcriptional cyclin-dependent kinases: Potential drug targets in cancer therapy

Eur J Med Chem. 2022 Feb 5:229:114056. doi: 10.1016/j.ejmech.2021.114056. Epub 2021 Dec 16.

Abstract

In the wake of the development of the concept of cell cycle and its limiting points, cyclin-dependent kinases (CDKs) are considered to play a central role in regulating cell cycle progression. Recent studies have strongly demonstrated that CDKs also has multiple functions, especially in response to extracellular and intracellular signals by interfering with transcriptional events. Consequently, how to inhibit their function has been a hot research topic. It is worth noting that the key role of CDKs in regulating transcription has been explored in recent years, but its related pharmacological targets are less developed, and most inhibitors have not entered the clinical stage. Accordingly, this perspective focus on the biological functions of transcription related CDKs and their complexes, some key upstream and downstream signals, and inhibitors for cancer treatment in recent years. In addition, some corresponding combined treatment strategies will provide a more novel perspective for future cancer remedy.

Keywords: Biological function; Cancer therapy; Selective transcriptional CDKs inhibitors; Transcriptional CDKs.

Publication types

  • Review

MeSH terms

  • Animals
  • Antineoplastic Agents / chemistry*
  • Antineoplastic Agents / pharmacology
  • Biomarkers, Tumor / metabolism*
  • Cyclin-Dependent Kinases / antagonists & inhibitors*
  • Drug Screening Assays, Antitumor
  • Humans
  • Pharmaceutical Preparations / chemistry*
  • Protein Binding
  • Protein Conformation
  • Protein Kinase Inhibitors / chemistry*
  • Protein Kinase Inhibitors / pharmacology
  • Signal Transduction
  • Structure-Activity Relationship

Substances

  • Antineoplastic Agents
  • Biomarkers, Tumor
  • Pharmaceutical Preparations
  • Protein Kinase Inhibitors
  • Cyclin-Dependent Kinases